It selectively degrades IKZF1 and IKZF3 at sub-nanomolar concentrations, exhibiting significant efficacy against various MM and DLBCL cell lines and xenograft models, even against lenalidomide-resistant cells. Here, IKZF1 is linked to Miyoshi myopathy.